Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Change in Account Payables (2022 - 2025)

Historic Change in Account Payables for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to -$37.4 million.

  • Axsome Therapeutics' Change in Account Payables fell 138393.41% to -$37.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.0 million, marking a year-over-year decrease of 12851.94%. This contributed to the annual value of $31.3 million for FY2024, which is 141002.89% up from last year.
  • According to the latest figures from Q3 2025, Axsome Therapeutics' Change in Account Payables is -$37.4 million, which was down 138393.41% from $6.0 million recorded in Q2 2025.
  • Axsome Therapeutics' 5-year Change in Account Payables high stood at $25.8 million for Q4 2022, and its period low was -$37.4 million during Q3 2025.
  • Over the past 4 years, Axsome Therapeutics' median Change in Account Payables value was $6.8 million (recorded in 2022), while the average stood at $2.7 million.
  • Its Change in Account Payables has fluctuated over the past 5 years, first surged by 56250.44% in 2024, then crashed by 138393.41% in 2025.
  • Axsome Therapeutics' Change in Account Payables (Quarter) stood at $25.8 million in 2022, then plummeted by 55.04% to $11.6 million in 2023, then crashed by 33.13% to $7.7 million in 2024, then crashed by 582.97% to -$37.4 million in 2025.
  • Its Change in Account Payables stands at -$37.4 million for Q3 2025, versus $6.0 million for Q2 2025 and $13.7 million for Q1 2025.